UPC — Universe Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.12m
- -$20.76m
- $23.02m
Annual income statement for Universe Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | R2022 September 30th | R2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 30.7 | 48 | 40.1 | 32.3 | 23 |
| Cost of Revenue | |||||
| Gross Profit | 14.1 | 25.3 | 21.9 | 10.3 | 6.07 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 20.5 | 34.4 | 47.2 | 36.3 | 31 |
| Operating Profit | 10.3 | 13.6 | -7.02 | -3.97 | -8.02 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 10.1 | 13.7 | -7.09 | -4.33 | -8.12 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 7.56 | 11.3 | -7.91 | -6.58 | -8.73 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 7.56 | 11.3 | -7.91 | -6.58 | -8.73 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 7.56 | 11.3 | -7.91 | -6.58 | -8.73 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 32.4 | 53.7 | -1,309 | -1,089 | -627 |